melanotan-2 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Cannabinoid receptor 1 (CB1) is colocalized on orexinergic projection neurons in the lateral hypothalamus and many output structures, where the CB1 and orexin receptor 1 (OX1) receptors physically and functionally join to form the CB1–OX1 receptor heterodimer. There is substantial anatomical and functional overlap and systemic cross-talk between the endocannabinoid system and orexin system within the central nervous system.
==== Marquez: The Wannabe B-Boy ==== Meet Marquez, a street fighter who makes life miserable for twins Richard and Edward. Mayhem brings in Brazilian jiu-jitsu specialist, Quinn Mulhern standing at 6'3 and weighing in at 177 lbs, with a record of 14 wins and 1 loss to put him in his place. This episode has never aired on American TV and is not available on the Bully Beatdown website like most other episodes. The episode has been aired in the Netherlands, the Fox8 channel of Foxtel and Austar in Australia, and MTV Latin America. Many have speculated that the bully winning more money is the reason why it was never broadcast in America.
== History == Brucella canis was first discovered in the United States by Leland Carmichael in 1966, when the bacterium was identified in canine vaginal discharge and the tissues from mass abortions in beagles. B. canis was said to be a biovar of B. suis. With recent research, PCR assay data was able to contradict B. canis and B. suis. PCR data showed a complete difference between the two strains along with B. suis biovars unattained from B. canis DNA. PCR assays have been proven beneficial when differentiating between Brucella strains and vaccine strains. Investigations into the bacterium revealed that domestic dogs are primarily affected along with other canine species. B. canis causes reproductive issues in female dogs, usually in the form of late-term spontaneous abortions. While in males, epididymitis, orchitis, and infertility were observed due to the bacterium. During the 1970s and 1980s, B. canis was reported in North America, Europe, and Asia. The reports were mainly from commercial breeding kennels wherein the bacterium can easily spread. Increase in infections were also attributed to the growing adoption of dogs as pets. By the 2000s, molecular analysis revealed that B. canis is unique from other Brucella species, categorized as a naturally occurring rough species that needs an anti-rough lipopolysaccharide reagent for detection. B. canis has been recognized as a growing zoonotic risk worldwide, having the ability to infect humans. Laboratory exposure or contact with pet dogs that had aborted fetuses were the main sources of exposure to the bacterium.
=== Adhesion molecules of the immune system === Springer began his research career in immunology by studying the molecular basis for cellular immunity using as an example the interaction of cytotoxic T lymphocytes with antigen-bearing target cells. None of the molecules involved in this interaction had yet been defined, including the long postulated antigen-specific T cell receptor. However, it was known that Mg2+ was required for immune cell-cell interactions, and that interaction between fibroblasts and the extracellular matrix was similarly Mg2+-dependent. Postulating that adhesion receptors were likely to be similar to antibodies and were unlikely to require magnesium, Springer hypothesized that other molecules must be required for antigen-specific interactions. He immunized animals with cytotoxic T lymphocytes and screened for monoclonal antibodies that blocked antigen-specific killing. Using this functional assay, his laboratory identified a set of lymphocyte function-associated (LFA) antigens required for cytotoxic T-cell-mediated killing and other T cell-dependent responses, including LFA-1 (CD11a/CD18), LFA-2 (CD2), and LFA-3 (CD58). Springer's group then identified ICAM-1 as a ligand for LFA-1, demonstrating that this interaction is required for efficient antigen recognition by cytotoxic T cells, and later discovered ICAM-2 (CD102) and ICAM-3 (CD50), which have two to five immunoglobulin (Ig)-like domains and comprise a subfamily of the Ig superfamily.
There are small amounts of 238Pu in the plutonium from usual reactors. However, isotopic separation would be quite expensive compared to another method: when 235U captures a neutron, it is converted to an excited state of 236U. Some of the excited 236U nuclei undergo fission, but some decay to the ground state of 236U by emitting gamma radiation. Further neutron capture creates 237U; which, with a half-life of 7 days, decays to 237Np. Since nearly all neptunium is produced in this way or consists of isotopes that decay quickly, one gets nearly pure 237Np. After chemical separation of neptunium, 237Np is again irradiated by reactor neutrons to be converted to 238Np, which decays to 238Pu with a half-life of 2 days.
Sources: en.wikipedia.org
=== STC1 === STC1 was discovered in 1995 from human kidney. It was demonstrated that human kidney extract produced the same calcium inhibitory action when injected in a fish. The gene that produce STC1, STC1 is located in the short arm of human chromosome 8 (position p21.2). STC1 mRNA is formed in heart, lung, liver, adrenal gland, prostate, and ovary, indicating that these are the sites of synthesis. Ovary contains the highest level of STC1 mRNA. Fish stanniocalcin and mammalian STC1 are closely related, and are about 50% similar in their structure. They are both responsible for calcium and phosphate balance. In mammals the predominant function of STC1 is to activate phosphate reabsorption in the small intestine and proximal tubules of the kidney.
Additionally, she starred in the one-shot X-Men: Sword of the Braddocks #1 in 2009 and the solo 4-issue series X-Men: Psylocke in 2010. During the Krakoan Age, Kwannon as Psylocke appeared in various team books such as the Hellions (2020) and Marauders (2022) and then starred in the one-shot X-Men: Blood Hunt – Psylocke #1 in 2024. As part of the X-Men: From the Ashes relaunch, Kwannon joined the main X-Men team, appearing in the 2024 series X-Men. Psylocke starred in a new solo ongoing series starting in November 2024. The character has been adapted in various media incarnations, including films, television series, and video games, having most notably been portrayed by Olivia Munn in the film X-Men: Apocalypse (2016). She is voiced by Naoko Mori in the second season of X-Men '97 (2026).
== Production == Approximately 1.5 million tons were produced in 1985, typically by the reaction of potassium chloride with sulfuric acid, analogous to the Mannheim process for producing sodium sulfate. The process involves intermediate formation of potassium bisulfate, an exothermic reaction that occurs at room temperature:
Gone with the Wind—first released in 1939—is generally considered to be the most successful film, with Guinness World Records in 2014 estimating its adjusted global gross at $3.4 billion. Estimates for Gone with the Wind's adjusted gross have varied substantially: its owner, Turner Entertainment, estimated its adjusted earnings at $3.3 billion in 2007, a few years earlier than the Guinness estimate; other estimates fall either side of this amount, with one putting its gross just under $3 billion in 2010, while another provided an alternative figure of $3.8 billion in 2006. Which film is Gone with the Wind's nearest rival depends on the set of figures used: Guinness had Avatar in second place with $3 billion, while other estimates saw Titanic in the runner-up spot with first-run worldwide earnings of almost $2.9 billion at 2010 prices.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.